Marinobufagenin may mediate the impact of salty diets on left ventricular hypertrophy by disrupting the protective function of coronary microvascular endothelium

Medical Hypotheses

Volumn 64, Issue 4, 2005, Pages 854-863

  McCarty, Mark F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MARINOBUFAGENIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLICOSANOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TRITERPENOID; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE; CELL MEMBRANE POTENTIAL; CORONARY BLOOD VESSEL; CORONARY MICROVASCULAR ENDOTHELIUM; DIABETIC NEPHROPATHY; DIET; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 13444256342     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.043     Document Type: Article

References (170)

1. Marcus M.L., Koyanagi S., Harrison D.G., Doty D.B., Hiratzka L.F., Eastham C.L. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am. J. Med. 75:1983;62-66
2. Rakusan K., Flanagan M.F., Geva T., Southern J., Van Praagh R. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation. 86:1992;38-46
3. Amann K., Buzello M., Simonaviciene A., Miltenberger-Miltenyi G., Koch A., Nabokov A., et al. Capillary/myocyte mismatch in the heart in renal failure-a role for erythropoietin? Nephrol. Dial. Transplant. 15:2000;964-969
4. Li X., Li R., Yu W., Shi H., Wei L. Characteristics of coronary microvascular lesions in autopsied elderly with hypertensive left ventricular hypertrophy. Chin. Med. J. (Engl.). 115:2002;658-663
5. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J. Hypertens. Suppl. 16:1998;S23-S29
6. Agabiti-Rosei E., Muiesan M.L. Prognostic significance of left ventricular hypertrophy regression. Adv. Exp. Med. Biol. 432:1997;199-205
7. Benjamin E.J., Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am. J. Med. Sci. 317:1999;168-175
8. Devereux R.B., Roman M.J. Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens. Res. 22:1999;1-9
9. Hanratty C., McAuley D., Silke B. Epidemiology and treatment of left ventricular hypertrophy in the elderly. Coron. Artery Dis. 10:1999;633-640
10. Armario P., del Rey R.H., Sanchez P., Martin-Baranera M., Torres G., Julia J., et al. Determinants of left ventricular mass in untreated mildly hypertensive subjects: hospitalet study in mild hypertension. Am. J. Hypertens. 12:1999;1084-1090
11. Beil A.H., Schmieder R.E., Messerli F.H. Salt intake, blood pressure, and cardiovascular structure. Cardiovasc. Drugs Ther. 8:1994;425-432
12. du C.G., Pellerin F., Wojewodska H., Ribstein J., Grolleau R., Mimran A. Determinants of left ventricular hypertrophy in hypertensive subjects that have never been treated: role of the sodium intake. Arch. Mal. Coeur. Vaiss. 82:1989;1105-1108
13. Langenfeld M.R., Schmieder R.E. Salt and left ventricular hypertrophy: what are the links? J. Hum. Hypertens. 9:1995;909-916
14. Schmieder R.E., Langenfeld M.R., Friedrich A., Schobel H.P., Gatzka C.D., Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation. 94:1996;1304-1309
15. Messerli F.H., Schmieder R.E., Weir M.R. Salt. A perpetrator of hypertensive target organ disease? Arch. Intern. Med. 157:1997;2449-2452
16. Campese V.M. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension. 23:1994;531-550
17. Heimann J.C., Drumond S., Alves A.T., Barbato A.J., Dichtchekenian V., Marcondes M. Left ventricular hypertrophy is more marked in salt-sensitive than in salt-resistant hypertensive patients. J. Cardiovasc. Pharmacol. 17(Suppl 2):1991;S122-S124
18. Musiari L., Ceriati R., Taliani U., Montesi M., Novarini A. Early abnormalities in left ventricular diastolic function of sodium-sensitive hypertensive patients. J. Hum. Hypertens. 13:1999;711-716
19. Ferrara L.A., de Simone G., Pasanisi F., Mancini M. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension. 6:1984;755-759
20. Jula A.M., Karanko H.M. Effects on left ventricular hypertrophy of long-term non-pharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation. 89:1994;1023-1031
21. Ozkahya M., Ok E., Cirit M., Aydin S., Akcicek F., Basci A., et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol. Dial. Transplant. 13:1998;1489-1493
22. de Simone G., Devereux R.B., Camargo M.J., Wallerson D.C., Sealey J.E., Laragh J.H. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am. J. Hypertens. 9:1996;216-222
23. Ennezat P.V., Houel R., Heloire F., Tolle V., Su J.B., Cohen A., et al. Effects of high sodium intake on ventricular remodeling in mice. Arch. Mal. Coeur Vaiss. 91:1998;935-939
24. Morgan T.O., Aubert J.F., Wang Q. Sodium, angiotensin II, blood pressure, and cardiac hypertrophy. Kidney Int. Suppl. 67:1998;S213-S215
25. Sugimoto K., Fujimura A., Takasaki I., Tokita Y., Iwamoto T., Takizawa T., et al. Effects of renin- angiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats. Hypertens. Res. 21:1998;163-168
26. Hirsch A.T., Pinto Y.M., Schunkert H., Dzau V.J. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am. J. Cardiol. 66:1990;22D-30D
27. Schunkert H., Dzau V.J., Tang S.S., Hirsch A.T., Apstein C.S., Lorell B.H. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J. Clin. Invest. 86:1990;1913-1920
28. Meggs L.G., Coupet J., Huang H., Cheng W., Li P., Capasso J.M., et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ. Res. 72:1993;1149-1162
29. Suzuki J., Matsubara H., Urakami M., Inada M. Rat angiotensin II (type 1 A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ. Res. 73:1993;439-447
30. lyer S.N., Raizada M.K., Katovich M.J. ATI receptor density changes during development of hypertension in hyperinsulinemic rats. Clin. Exp. Hypertens. 18:1996;793-810
31. Fareh J., Touyz R.M., Schiffrin E.L., Thibault G. Cardiac type-1 angiotensin II receptor status in deoxycorticosterone acetate-salt hypertension in rats. Hypertension. 30:1997;1253-1259
32. Ritchie R.H., Marsb J.D., Lancaster W.D., Diglio C.A., Schiebinger R.J. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension. 31:1998;39-44
33. Lijnen P., Petrov V. Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Meth. Find Exp. Clin. Pharmacol. 21:1999;363-374
34. Brilla C.G., Scheer C., Rupp H. Renin-rangiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J. Hypertens. Suppl. 15:1997;S13-S19
35. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens. 5:1992;95-110
36. Dahlof B. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press. Suppl. 2:1994;35-40
37. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 275:1996;1507-1513
38. Carson P., Giles T., Higginbotham M., Hollenberg N., Kannel W., Siragy H.M. Angiotensin receptor blockers: evidence for preserving target organs. Clin. Cardiol. 24:2001;183-190
39. White M. Cardioprotective effect of angiotensin II receptor antagonists. Can. J. Cardiol. 15(Suppl F):1999;10F-14F
40. Diamond J.A., Gharavi A., Roychoudhury D., Machac J., Henzlova M.J., Travis A., et al. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group. Curr. Med. Res. Opin. 15:1999;1-8
41. Hartman J.C. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann. Thorac. Surg. 60:1995;789-792
42. Gohlke P., Linz W., Scholkens B.A., Kuwer I., Bartenbach S., Schnell A., et al. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension. 23:1994;411-418
43. Linz W., Wiemer G., Scholkens B.A. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J. Mol. Cell Cardiol. 24:1992;909-919
44. Ritchie R.H., Schiebinger R.J., LaPointe M.C., Marsh J.D. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am. J. Physiol. 275:1998;H1370-H1374
45. Shah A.M., MacCarthy P.A. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol. Ther. 86:2000;49-86
46. MacCarthy P.A., Grieve D.J., Li J.M., Dunster C., Kelly F.J., Shah A.M. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation. 104:2001;2967-2974
47. Ackermann A., Fernandez-Alfonso M.S., Sanchez D.R., Ortega T., Paul M., Gonzalez C. Modulation of angiotensin-converting enzyme by nitric oxide. Br. J. Pharmacol. 124:1998;291-298
48. Usui M., Egashira K., Kitamoto S., Koyanagi M., Katoh M., Kataoka C., et al. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension. 34:1999;546-551
49. Cahill P.A., Redmond E.M., Foster C., Sitzmann J.V. Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells. Eur. J. Pharmacol. 288:1995;219-229
50. Ichiki T., Usui M., Kato M., Funakoshi Y., Ito K., Egashira K., et al. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 31:1998;342-348
51. Katoh M., Egashira K., Usui M., Ichiki T., Tomita H., Shimokawa H., et al. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ. Res. 83:1998;743-751
52. Millatt L.J., Abdel-Rahman E.M., Siragy H.M. Angiotensin II and nitric oxide: a question of balance. Regul. Pept. 81:1999;1-10
53. Linz W., Wiemer G., Schaper J., Zimmermann R., Nagasawa K., Gohlke P., et al. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol. Cell Biochem. 147:1995;89-97
54. Gerova M., Hartmannova B., Dolezel S., Jezek L. Long-term inhibition of NO synthase induces cardiac hypertrophy with a decrease in adrenergic innervation. Physiol. Res. 45:1996;339-344
55. Bernatova I., Pechanova O., Pelouch V., Simko F. Regression of chronic L -NAME-treatment- induced left ventricular hypertrophy: effect of captopril. J. Mol. Cell Cardiol. 32:2000;177-185
56. Simko F., Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol. Res. 49:2000;37-46
57. Pacca S.R., de Azevedo A.P., De Oliveira C.F., De L.I., De Nucci G., Antunes E. Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 39:2002;201-207
58. Haddy F.J., Overbeck H.W. The role of humoral agents in volume expanded hypertension. Life Sci. 19:1976;935-947
59. MacGregor G.A., de Wardener H.E. Is a circulating sodium transport inhibitor involved in the pathogenesis of essential hypertension? Clin. Exp. Hypertens. 3:1981;815-830
60. Haddy F.J. Natriuretic hormone-the missing link in low renin hypertension? Biochem. Pharmacol. 31:1982;3159-3161
61. Blaustein M.P., Hamlyn J.M. Sodium transport inhibition, cell calcium, and hypertension. The natriuretic hormone/Na+-Ca2+ exchange/hypertension hypothesis. Am. J. Med. 77:1984;45-59
62. Haddy F.J., Pamnani M.B. Role of ouabain-like factors and Na-K-ATPase inhibitors in hypertension-some old and recent findings. Clin. Exp. Hypertens. 20:1998;499-508
63. Fedorova O.V., Doris P.A., Bagrov A.Y. Endogenous marinobufagenin-like factor in acute plasma volume expansion. Clin. Exp. Hypertens. 20:1998;581-591
64. Fedorova O.V., Kolodkin N.I., Agalakova N.I., Lakatta E.G., Bagrov A.Y. Marinobufagenin, an endogenous α-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats. Hypertension. 37:2001;462-466
65. Fedorova O.V., Talan M.I., Agalakova N.I., Lakatta E.G., Bagrov A.Y. Endogenous ligand of α (l) sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation. 105:2002;1122-1127
66. Fedorova O.V., Bagrov A.Y. Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different α-subunit isoforms. Am. J. Hypertens. 10:1997;929-935
67. Cappuccio F.P., Markandu N.D., Sagnella G.A., MacGregor G.A. The effect of oral digoxin on sodium excretion, renin-angiotensin-aldosterone system and blood pressure in normotensive subjects. Postgrad. Med. J. 62:1986;265-268
68. Dmitrieva R.I., Bagrov A.Y., Lalli E., Sassone-Corsi P., Stocco D.M., Doris P.A. Mammalian bufadienolide is synthesized from cholesterol in the adrenal cortex by a pathway that Is independent of cholesterol side-chain cleavage. Hypertension. 36:2000;442-448
69. Fedorova O.V., Lakatta E.G., Bagrov A.Y. Endogenous Na, K pump ligands are differentially regulated during acute NaCl loading of Dahl rats. Circulation. 102:2000;3009-3014
70. Fridman A.I., Matveev S.A., Agalakova N.I., Fedorova O.V., Lakatta E.G., Bagrov A.Y. Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J. Hypertens. 20:2002;1189-1194
71. Gonick H.C., Ding Y., Vaziri N.D., Bagrov A.Y., Fedorova O.V. Simultaneous measurement of marinobufagenin, ouabain, and hypertension- associated protein in various disease states. Clin. Exp. Hypertens. 20:1998;617-627
72. Lopatin D.A., Ailamazian E.K., Dmitrieva R.I., Shpen V.M., Fedorova O.V., Doris P.A., et al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J. Hypertens. 17:1999;1179-1187
73. Blaustein M.P. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am. J. Physiol. 232:1977;C165-C173
74. Perry I.J., Beevers D.G. Salt intake and stroke: a possible direct effect. J. Hum. Hypertens. 6:1992;23-25
75. Xie J.X., Sasaki S., Joossens J.V., Kesteloot H. The relationship between urinary cations obtained from the INTERSALT study and cerebrovascular mortality. J. Hum. Hypertens. 6:1992;17-21
76. Fransen P., Hendrickx J., Brutsaert D.L., Sys S.U. Distribution and role of Na (+)/K (+) ATPase in endocardial endothelium. Cardiovasc. Res. 52:2001;487-499
77. Haddy F.J. Potassium, Na+-K+ pump inhibitor and low-renin hypertension. Clin. Invest. Med. 10:1987;547-554
78. Glitsch H.G. Electrophysiology of the sodium-potassium-ATPase in cardiac cells. Physiol. Rev. 81:2001;1791-1826
79. Busse R., Luckhoff A., Mulsch A. Cellular mechanisms controlling EDRF/NO formation in endothelial cells. Basic Res. Cardiol. 86(Suppl 2):1991;7-16
80. He P., Curry F.E. Endothelial cell hyperpolarization increases [Ca2+]i and venular microvessel permeability. J. Appl. Physiol. 76:1994;2288-2297
81. McCabe R.D., Bakarich M.A., Srivastava K., Young D.B. Potassium inhibits free radical formation. Hypertension. 24:1994;77-82
82. al-Mehdi A.B., Ischiropoulos H., Fisher A.B. Endothelial cell oxidant generation during K (+)-induced membrane depolarization. J. Cell Physiol. 166:1996;274-280
83. McCarty M.F. Endothelial membrane potential regulates production of both nitric oxide and superoxide - a fundamental determinant of vascular health. Med. Hypotheses. 53:1999;277-289
84. Sohn H.Y., Keller M., Gloe T., Morawietz H., Rueckschloss U., Pohl U. The small G-protein Rac mediates depolarization-induced superoxide formation in human endothelial cells. J. Biol. Chem. 275:2000;18745-18750
85. Meyer J.W., Holland J.A., Ziegler L.M., Chang M.M., Beebe G., Schmitt M.E. Identification of a functional leukocyte-type NADPH oxidase in human endothelial cells:a potential atherogenic source of reactive oxygen species. Endothelium. 7:1999;11-22
86. Zhang H., Schmeisser A., Garlichs C.D., Plotze K., Damme U., Mugge A., et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. 44:1999;215-222
87. Holland J.A., O'Donnell R.W., Chang M.M., Johnson D.K., Ziegler L.M. Endothelial cell oxidant production: effect of NADPH oxidase inhibitors. Endothelium. 7:2000;109-119
88. Meyer J.W., Schmitt M.E. A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Lett. 472:2000;1-4
89. Katusic Z.S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am. J. Physiol. Heart Circ. Physiol. 281:2001;H981-H986
90. Boegehold M.A. Flow-dependent arteriolar dilation in normotensive rats fed low- or high-salt diets. Am. J. Physiol. 269:1995;H1407-H1414
91. Lenda D.M., Sauls B.A., Boegehold M.A. Reactive oxygen species may contribute to reduced endothelium-dependent dilation in rats fed high salt. Am. J. Physiol. Heart Circ. Physiol. 279:2000;H7-H14
92. Li J.M., Mullen A.M., Shah A.M. Phenotypic properties and characteristics of superoxide production by mouse coronary microvascular endothelial cells. J. Mol. Cell Cardiol. 33:2001;1119-1131
93. Li J.M., Mullen A.M., Yun S., Wientjes F., Brouns G.Y., Thrasher A.J., et al. Essential role of the NADPH oxidase subunit p47 (phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ. Res. 90:2002;143-150
94. Lang D., Mosfer S.I., Shakesby A., Donaldson F., Lewis M.J. Coronary microvascular endothelial cell redox state in left ventricular hypertrophy: the role of angiotensin II. Circ. Res. 86:2000;463-469
95. Milstien S., Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem. Biophys. Res. Commun. 263:1999;681-684
96. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 287:2002;1420-1426
97. McCarty MF. Coping with endothelial superoxide: potential complementarity of arginine and high-dose folate. Med Hypotheses 2004; in press
98. Wagner A.H., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors tarough attenuation of endothelial superoxide anion formation. Arterioscler Thromb. Vase. Biol. 20:2000;61-69
99. Thakur N.K., Hayashi T., Sumi D., Kano H., Tsunekawa T., Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H75-H83
100. Wassmann S., Laufs U., Baumer A.T., Muller K., Ahlbory K., Linz W., et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 37:2001;1450-1457
101. Laufs U., La F., Plutzky V., Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135
102. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273:1998;24266-24271
103. Laufs U., Gertz K., Dirnagl U., Bohm M., Nickenig G., Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 942:2002;23-30
104. Luo J.D., Zhang W.W., Zhang G.P., Guan J.X., Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin. Exp. Pharmacol. Physiol. 26:1999;903-908
105. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 105:2002;868-873
106. Oi S., Haneda T., Osaki J., Kashiwagi Y., Nakamura Y., Kawabe J., et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur. J. Pharmacol. 376:1999;139-148
107. Gouni-Berthold I., Berthold H.K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am. Heart J. 143:2002;356-365
108. Menendez R., Amor A.M., Rodeiro I., Gonzalez R.M., Gonzalez P.C., Alfonso J.L., et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch. Med. Res. 32:2001;8-12
109. Cooke J.P., Oka R.K. Atherogenesis and the arginine hypothesis. Curr. Atheroscler. Rep. 3:2001;252-259
110. Verhaar M.C., Stroes E., Rabelink T.J. Folates and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 22:2002;6-13
111. Zoccali C., Mallamaci F., Maas R., Benedetto F.A., Tripepi G., Malatino L.S., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 62:2002;339-345
112. Avolio A.P., Clyde K.M., Beard T.C., Cooke H.M., Ho K.K., O'Rourke M.F. Improved arterial distensibility in normotensive subjects on a low salt diet. Arteriosclerosis. 6:1986;166-169
113. McCarty M.F. Monoselenolipoic acid may be an outstanding pharmaceutical antioxidant with direct thioredoxin-like activity. Med. Hypotheses. 55:2000;185-186
114. Safar M.E., Thuilliez C., Richard V., Benetos A. Pressure-independent contribution of sodium to large artery structure and function in hypertension. Cardiovasc. Res. 46:2000;269-276
115. Seals D.R., Tanaka H., Clevenger C.M., Monahan K.D., Reiling M.J., Hiatt W.R., et al. Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. J. Am. Coll. Cardiol. 38:2001;506-513
116. Kinlay S., Creager M.A., Fukumoto M., Hikita H., Fang J.C., Selwyn A.P., et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension. 38:2001;1049-1053
117. Fitch R.M., Vergona R., Sullivan M.E., Wang Y.X. Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovasc. Res. 51:2001;351-358
118. Wilkinson I.B., MacCallum H., Cockcroft J.R., Webb D.J. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br. J. Clin. Pharmacol. 53:2002;189-192
119. Tobian L. Salt and hypertension. Lessons from animal models that relate to human hypertension. Hypertension. 17:1991;152-158
120. Lee R.M., Triggle C.R. Morphometric study of mesenteric arteries from genetically hypertensive Dahl strain rats. Blood Vessels. 23:1986;199-224
121. Hampton J.A., Bernardo D.A., Khan N.A., Lacher D.A., Rapp J.P., Gohara A.F., et al. Morphometric evaluation of the renal arterial system of Dahl salt-sensitive and salt-resistant rats on a high salt diet. JI. Interlobular arteries and intralobular arterioles. Lab. Invest. 60:1989;839-846
122. Labat C., Lacolley P., Lajemi M., de Gasparo M., Safar M.E., Benetos A. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension. 38:2001;439-443
123. Hayakawa H., Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension. 29:1997;235-241
124. Mathew R., Fan N.Y., Yuan N., Chander P.N., Gewitz M.H., Stier C.T.J. Inhibition of NOS enhances pulmonary vascular changes in stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Lung Cell Mol. Physiol. 278:2000;L81-L89
125. Luscher T.F., Raij L., Vanhoutte P.M. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 9:1987;157-163
126. Miyoshi A., Suzuki H., Fujiwara M., Masai M., Iwasaki T. Impairment of endothelial function in salt-sensitive hypertension in humans. Am. J. Hypertens. 10:1997;1083-1090
127. Liu Y., Rusch N.J., Lombard J.H. Loss of endothelium and receptor-mediated dilation in pial arterioles of rats fed a short-term high salt diet. Hypertension. 33:1999;686-688
128. Lenda D.M., Sauls B.A., Boegehold M.A. Reactive oxygen species may contribute to reduced endothelium-dependent dilation in rats fed high salt. Am. J. Physiol. Heart Circ. Physiol. 279:2000;H7-H14
129. Somers M.J., Mavromatis K., Galis Z.S., Harrison D.G. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 101:2000;1722-1728
130. Bragulat E., de la Sierra A., Antonio M.T., Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 37:2001;444-448
131. Kagota S., Tamashiro A., Yamaguchi Y., Nakamura K., Kunitomo M. High salt intake impairs vascular nitric oxide/cyclic guanosine monophosphate system in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 302:2002;344-351
132. Alien T.J., Waldron M.J., Casley D., Jerums G., Cooper M.E. Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes. 46:1997;19-24
133. Dworkin L.D., Benstein J.A., Tolbert E., Feiner H.D. Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. J. Am. Soc. Nephrol. 7:1996;437-442
134. Alien T.J., Waldron M.J., Casley D., Jerums G., Cooper M.E. Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes. 46:1997;19-24
135. Cianciaruso B., Bellizzi V., Minutolo R., Tavera A., Capuano A., Conte G., et al. Salt intake and renal outcome in patients with progressive renal disease. Miner. Electrolyte Metab. 24:1998;296-301
136. Campese V.M., Parise M., Karubian F., Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension. 18:1991;805-812
137. Hayakawa H., Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension. 31:1998;266-270
138. Zhou X.J., Vaziri N.D., Zhang J., Wang H.W., Wang X.Q. Association of renal injury with nitric oxide deficiency in aged SHR: Prevention by hypertension control with ATI blockade. Kidney Int. 62:2002;914-921
139. Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol. Dial. Transplant. 16(Suppl 1):1902;60-62
140. Fujiwara N., Osanai T., Kamada T., Katoh T., Takahashi K., Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension:modulation of nitric oxide synthesis by salt intake. Circulation. 101:2000;856-861
141. Facchini F.S., DoNascimento C., Reaven G.M., Yip J.W., Ni X.P., Humphreys M.H. Blood pressure, sodium intake, insulin resistance, and urinary nitrate excretion. Hypertension. 33:1999;1008-1012
142. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 95:1998;8880-8885
143. McCarty M.F. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke -just say NO to stroke! Med. Hypotheses. 55:2000;386-403
144. Rehman A., Rahman A.R., Rasool A.H. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors. J. Hum. Hypertens. 16:2002;261-266
145. Mahmud A., Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am. J. Hypertens. 15:2002;321-325
146. Bataineh A., Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int. Suppl. 68:1998;S14-S19
147. McCarty MF. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine - an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med Hypotheses 2004; in press
148. Matsuoka H., Itoh S., Kimoto M., Kohno K., Tamai O., Wada Y., et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension. 29:1997;242-247
149. Bagrov A.Y., Roukoyatkina N.I., Pinaev A.G., Dmitrieva R.I., Fedorova O.V. Effects of two endogenous Na+,K (+)-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta. Eur. J. Pharmacol. 274:1995;151-158
150. Bagrov A.Y., Fedorova O.V. Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+, K+-pump in human mesenteric arteries. J. Hypertens. 16:1998;1953-1958
151. de Wardener H.E., MacGregor G.A. Harmful effects of dietary salt in addition to hypertension. J. Hum. Hypertens. 16:2002;213-223
152. Dahl L.K. Salt and hypertension. Am. J. Clin. Nutr. 25:1972;231-244
153. Page L.B., Damon A., Moellering R.C.J. Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation. 49:1974;1132-1146
154. Meneely G.R., Battarbee H.D. High sodium-low potassium environment and hypertension. Am. J. Cardiol. 38:1976;768-785
155. Trowell H.C. Hypertension, obesity, diabetes mellitus and coronary heart disease. Trowell H.C., Burkitt D.P. Western diseases: their emergence and prevention. 1981;3-32 Harvard University Press, Cambridge, MA
156. Carvalho J.J., Baruzzi R.G., Howard P.F., Poulter N., Alpers M.P., Franco L.J., et al. Blood pressure in four remote populations in the INTERSALT Study. Hypertension. 14:1989;238-246
157. Lindeberg S., Lundh B. Apparent absence of stroke and ischaemic heart disease in a traditional Melanesian island: a clinical study in Kitava. J. Intern. Med. 233:1993;269-275
158. Geleijnse J.M., Hofman A., Witteman J.C., Hazebroek A.A., Valkenburg H.A., Grobbee D.E. Long-term effects of neonatal sodium restriction on blood pressure. Hypertension. 29:1997;913-917
159. Weinberger M.H. Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans. J. Clin. Hypertens. (Greenwich). 4:2002;274-276
160. He F.J., Markandu N.D., Sagnella G.A., MacGregor G.A. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension. 32:1998;820-824
161. Alderman M.H. Salt, blood pressure, and human health. Hypertension. 36:2000;890-893
162. Alderman M.H., Ooi W.L., Cohen H., Madhavan S., Sealey J.E., Laragh J.H. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens. 10:1997;1-8
163. Alderman M.H., Madhavan S., Cohen H., Sealey J.E., Laragh J.H. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension. 25:1995;1144-1152
164. Alderman M.H., Cohen H., Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet. 351:1998;781-785
165. de Wardener H., MacGregor G.A. Sodium intake and mortality. Lancet. 351:1998;1508-1510
166. de Wardener H.E. Salt reduction and cardiovascular risk: the anatomy of a myth. J. Hum. Hypertens. 13:1999;1-4
167. van Buren M., Rabelink A.J., Bijlsma J.A., Koomans H.A. Natriuretic and kaliuretic response to potassium load: modulation by sodium intake. Nephrol. Dial. Transplant. 8:1993;495-500
168. Krishna G.G., Kapoor S.C. Potassium supplementation ameliorates mineralocorticoid-induced sodium retention. Kidney Int. 43:1993;1097-1103
169. Coruzzi P., Brambilla L., Brambilla V., Gualerzi M., Rossi M., Parati G., et al. Potassium depletion and salt sensitivity in essential hypertension. J. Clin. Endocrinol. Metab. 86:2001;2857-2862
170. Corti R., Burnett J.C.J., Rouleau J.L., Ruschitzka F., Luscher T.F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 104:2001;1856-1862